Modulation of sensitivity to cis-diamminedichloroplatinum (II) bp thromboxane A2 receptor antagonists in non-small-cell lung cancer cell lines

British Journal of Cancer

Volumn 74, Issue 10, 1996, Pages 1553-1558

  Kasahara, K ^a   Fujimura, M ^a   Bando, T ^a   Shibata, K ^a   Shirasaki, H ^a   Matsuda, T ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

Cisplatin resistance; K+ ATPase; Na+; Thromboxane A2 receptor antagonist

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); CARBOPLATIN; CISPLATIN; DOMITROBAN; GLUTATHIONE; GLUTATHIONE TRANSFERASE; PLATINUM; SERATRODAST; THROMBOXANE A2 RECEPTOR BLOCKING AGENT;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG RESISTANCE; DRUG SENSITIVITY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL;

EID: 0029855711     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.588     Document Type: Article

References (27)

1. ANDREWS PA, VELURY S, MANN SC AND HOWELL SB. (1988). Cis-diamminedichloroplatinum (II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res., 48, 68-73.
2. ANDREWS PA AND HOWELL SB. (1990). Cellular pharmacology of cisplatin: perspective on mechanisms of acquired resistance. Cancer Cells, 2, 35-43.
3. +-adenosine triphosphatase in the accumulation of cis-diamminedichloroplatinum (II) in human ovarian carcinoma cells. Cancer Res., 51, 3677-3681.
4. BERENBAUM MC. (1989). What is synergy? Pharmacol. Rev., 41, 93-141.
5. 2 receptor ligand (S-145) in platelets and vascular and airway smooth muscle. J. Pharmacol. Exp. Therap., 262, 784-791.
6. EASTMAN A AND SCHULTE N. (1988). Enhanced DNA repair as a mechanism of resistance to Cis-diamminedichloroplatinum (II). Biochemistry, 27, 4730-4734.
7. FUJIWARA Y, SUGIMOTO Y, KASAHARA K, BUNGO M, YAMAKIDO M, TEW KD AND SAIJO N. (1990). Determinants of drug response in a cisplatin-resistant human lung cancer cell line. Jpn. J. Cancer Res., 81, 527-535.
8. GRIFFITH OW. (1980). Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine. Anal. Biochem., 106, 207-212.
9. HABIG WH, PABST MJ AND JAKOBY WB. (1974). Glutathione S-transferase. J. Biol. Chem., 249, 7130-7139.
10. HROMAS RA, ANDREWS PA, MURPHY MP AND BURNS CP. (1987). Glutathione depletion reverses cisplatin resistance in murine L1210 leukemia cells. Cancer Lett., 34, 9-13.
11. KASAHARA K, FUJIWARA Y, NISHIO K, OHMORI T, SUGIMOTO Y, KOMIYA K, MATSUDA T AND SAIJO N. (1991). Metallothionein content correlates with the sensitivity of human small cell lung cancer lines to cisplatin. Cancer Res., 51, 3237-3242.
12. KUROKAWA T, MATSUMOTO T, ASHIDA Y, SASADA R AND IWASA S. (1994). Antagonism of the human thromboxane A receptor by and anti-asthmatic agent AA-2414. Biol. Pharm. Bull., 17, 383-385.
13. LOETHER PJ AND EINHORN LH. (1984). Cisplatin. Ann. Intern. Med., 100, 704-713.
14. MANN SC, ANDREWS PA AND HOWELL SB. (1990). Short-term cis-diamminedichloroplatinum (II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Chemother. Pharmacol., 25, 236-240.
15. MANN SC, ANDREWS PA AND HOWELL SB. (1991). Modulation of cis-diamminedichloroplatinum(II) accumulation and sensitivity by forskin and 3-isobutyl-1-methylxanthine in sensitive and resistant human ovarian carcinoma cells. Int. J. Cancer, 48, 866-872.
16. MORIKAGE T, OHMORI T, NISHIO K, FUJIWARA Y, TAKEDA Y AND SAIJO N. (1993). Modulation of cisplatin sensitivity and accumulation by amphotericin B in cisplatin-resistant human lung cancer cell lines. Cancer Res., 53, 3302-3307.
17. 2 in plasma samples from patients with benign and malignant tumors of breast. Prostaglandins, 29, 513-528.
18. 2: a receptor-mediated event. Adv. Prostgl. Thrombox. Leukotr. Res., 21, 925-928.
19. NISHIO K, SUGIMOTO Y, NAKAGAWA K, NIIMI S, FUJIWARA Y, BUNCO M, KASAHARA K, FUJIKI H AND SAIJO N. (1990). Cross-resistance to tumor promoters in human cancer cell lines resistant to adriamycin and cisplatin. Br. J. Cancer, 62, 415-419.
20. OATES JA, FITZGERALD GA, BRANCH RA, JACKSON EK, KNAPPH R AND ROBERS III L. (1988). Clinical implication of prostaglandin and thromboxane A2 formation. N. Engl. J. Med., 319, 689-698.
21. OHMORI T., NISHIO K., OHTA S., KUBOTA N., ADACHI M., KOMIYA K AND SAIJO N. (1994). Ouabain-resistant non-small cell-lung cancer cell line shows collateral sensitivity to cis-diamminedichloroplatinum (II) (CDDP). Int J. Cancer, 57, 111-116.
22. ROBERTS JJ AND KOTSALI-KOABTSI VP. (1986). Potentiation of sulphur mustard or cisplatin-induced toxicity by caffeine in Chinese hamster cells correlates with formation of DNA double strand breaks during replication on damaged template. Mutat. Res., 165, 207-220.
23. SCHIANO MA, SEVIN BU, PERRAS J, RAMOS R, WOLLOCH EH AND AVERETTE HE. (1991). In vitro enhancement of cis-platinum antitumor activity by caffeine and pentoxifylline in a human ovarian cell line. Gynecol. Oncol., 43, 37-45.
24. STEEL GG AND PECKMAN MJ. (1979). Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int. J. Radat. Oncol., 5, 85-91.
25. TEICHER BA, KOUBUIT TT, MENON K, HOLDEN SA AND ARA G. (1994). Cyclooxygenase and lipoxygenase inhibitors as modulation of cancer therapies. Cancer Chemother. Pharmacol., 33, 515-522.
26. TIMMER-BOSSCHA H, MULDER NH AND DE VRIES EGE. (1992). Modulation of cis-diamminedichloroplatinum (II) resistance: a review. Br. J. Cancer, 66, 227-238.
27. USHIKUBI F, AIBA Y, NAKAMURA K, NAMBA T, HIRATA M, MAZUDA O, KATSURA Y AND NARUMIYA S. (1993). Thromboxane A2 receptor is highly expressed in mouse immature thymocytes and mediates DNA fragmentation and apoptosis. J. Exp. Med., 178, 1825-1830.